1.
Akiko Uchida, Yasushi Isobe, Junko Asano, Yu Uemura, Masahiro Hoshikawa, Masayuki Takagi, Ikuo Miura. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements. Haematologica 2019;104(7):1417-1421; https://doi.org/10.3324/haematol.2018.204958.